Alise S Reicin
Overview
Explore the profile of Alise S Reicin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
507
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hao K, Bosse Y, Nickle D, Pare P, Postma D, Laviolette M, et al.
PLoS Genet
. 2012 Dec;
8(11):e1003029.
PMID: 23209423
Genome-wide association studies (GWAS) have identified loci reproducibly associated with pulmonary diseases; however, the molecular mechanism underlying these associations are largely unknown. The objectives of this study were to discover...
2.
Zhao F, Williams M, Welsh D, Meng X, Ritter A, Abbadie C, et al.
Pain
. 2009 Jun;
145(1-2):110-9.
PMID: 19560271
Spinal cord fMRI offers an excellent opportunity to quantify nociception using neuronal activation induced by painful stimuli. Measurement of the magnitude of stimulation-induced activation, and its suppression with analgesics can...
3.
Curtis S, Ko A, Bolognese J, Cavanaugh P, Reicin A
Curr Med Res Opin
. 2007 Feb;
22(12):2365-74.
PMID: 17265571
Background: A pooled analysis of randomized clinical trials data was performed to compare the rate of thrombotic cardiovascular events (thrombotic events) in patients taking the COX-2 selective inhibitor (coxib) etoricoxib,...
4.
Cannon C, Curtis S, FitzGerald G, Krum H, Kaur A, Bolognese J, et al.
Lancet
. 2006 Nov;
368(9549):1771-81.
PMID: 17113426
Background: Cyclo-oxygenase-2 (COX-2) selective inhibitors have been associated with an increased risk of thrombotic cardiovascular events in placebo-controlled trials, but no clinical trial has been reported with the primary aim...
5.
Reiff A, Lovell D, van Adelsberg J, Kiss M, Goodman S, Zavaler M, et al.
J Rheumatol
. 2006 Apr;
33(5):985-95.
PMID: 16583464
Objective: To compare the safety and efficacy of rofecoxib* to naproxen for the treatment of juvenile rheumatoid arthritis (JRA). Methods: This was a 12-week, multicenter, randomized, double-blind, double-dummy, active comparator-controlled,...
6.
Sinatra R, Boice J, Loeys T, Ko A, Kashuba M, Jahr J, et al.
Reg Anesth Pain Med
. 2006 Mar;
31(2):134-42.
PMID: 16543099
Background And Objectives: In this randomized, placebo-controlled, double-blind study, the efficacy and safety of rofecoxib 50 mg was evaluated in patients undergoing major abdominal gynecologic surgery. Methods: Patients were randomized...
7.
Curtis S, Bockow B, Fisher C, Olaleye J, Compton A, Ko A, et al.
BMC Musculoskelet Disord
. 2005 Dec;
6:58.
PMID: 16321158
Background: The aim of this study was to evaluate the long-term efficacy and tolerability of etoricoxib, a COX-2 selective inhibitor, in osteoarthritis (OA) patients. Methods: A double-blind, randomized, multicenter study...
8.
Tsoukas C, Eyster M, Shingo S, Mukhopadhyay S, Giallella K, Curtis S, et al.
Blood
. 2005 Nov;
107(5):1785-90.
PMID: 16291600
This 2-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy. In part 1 (6 weeks),...
9.
Lynn Rasmussen G, Malmstrom K, Bourne M, Jove M, Rhondeau S, Kotey P, et al.
Anesth Analg
. 2005 Sep;
101(4):1104-1111.
PMID: 16192529
Unlabelled: In this randomized, double-blind, placebo-controlled, multicenter study we assessed the analgesic effect of etoricoxib (a new cyclooxygenase-2 inhibitor) in patients having had knee or hip replacement surgery. A total...
10.
Ramey D, Watson D, Yu C, Bolognese J, Curtis S, Reicin A
Curr Med Res Opin
. 2005 Jun;
21(5):715-22.
PMID: 15974563
Objective: In spite of numerous studies demonstrating the serious gastrointestinal (GI) toxicity associated with non-selective non-steroidal anti-inflammatory drugs (NSAIDs), many patients at high GI risk continue to receive prescriptions for...